Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.64)
# 806
Out of 5,140 analysts
109
Total ratings
52.31%
Success rate
7.37%
Average return
Main Sectors:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CTMX CytomX Therapeutics | Maintains: Overweight | $6 → $10 | $5.43 | +84.16% | 2 | Feb 4, 2026 | |
| INSM Insmed | Maintains: Overweight | $216 → $230 | $164.91 | +39.47% | 1 | Dec 16, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Overweight | $4 | $1.76 | +127.27% | 1 | Dec 11, 2025 | |
| VNDA Vanda Pharmaceuticals | Maintains: Overweight | $13 → $11 | $5.76 | +90.97% | 2 | Oct 30, 2025 | |
| GOSS Gossamer Bio | Reiterates: Overweight | n/a | $2.13 | - | 1 | Sep 11, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $405 → $525 | $473.42 | +10.90% | 2 | Sep 10, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $64.08 | +40.45% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $476.90 | +0.65% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $60.66 | -9.33% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $151.40 | -47.16% | 10 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $12.04 | - | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $1,015 | $779.67 | +30.18% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $405 | $374.75 | +8.07% | 2 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $220 | $336.19 | -34.56% | 23 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $10 | $14.40 | -30.56% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6.5 | $5.54 | +17.33% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $53.46 | +34.68% | 1 | Apr 13, 2023 |
CytomX Therapeutics
Feb 4, 2026
Maintains: Overweight
Price Target: $6 → $10
Current: $5.43
Upside: +84.16%
Insmed
Dec 16, 2025
Maintains: Overweight
Price Target: $216 → $230
Current: $164.91
Upside: +39.47%
Inhibikase Therapeutics
Dec 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.76
Upside: +127.27%
Vanda Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $5.76
Upside: +90.97%
Gossamer Bio
Sep 11, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.13
Upside: -
United Therapeutics
Sep 10, 2025
Maintains: Overweight
Price Target: $405 → $525
Current: $473.42
Upside: +10.90%
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $64.08
Upside: +40.45%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $476.90
Upside: +0.65%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $60.66
Upside: -9.33%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $151.40
Upside: -47.16%
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $12.04
Upside: -
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $779.67
Upside: +30.18%
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $374.75
Upside: +8.07%
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $336.19
Upside: -34.56%
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $14.40
Upside: -30.56%
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $5.54
Upside: +17.33%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $53.46
Upside: +34.68%